UHF Alberta Government Novo Nordisk partnership logo

A Major Partnership to Tackle Diabetes

Novo Nordisk Canada Inc., in partnership with the University Hospital Foundation and the Government of Alberta Ministry of Economic Development and Trade, announces the Novo Nordisk Alberta Diabetes Fund (NOVAD), to advance innovations long-term health outcomes, quality of life, and economic prosperity for Albertans suffering with diabetes and obesity.

The partnership focuses on three objectives:

  • Improving diabetes-obesity interventions and management in the community setting for the most vulnerable patients
  • Enhancing diabetes-obesity interventions and management for seniors, to support independent living
  • Improving acute care for patients presenting in hospital with diabetes

Partnership quote from Novo Nordisk Canada president

The prevention, diagnosis and treatment of diabetes is a key factor in improving the health of Albertans. In 2016, 300,000 Albertans – or 7.5% of the population - were known to have diabetes. The prevalence of diabetes increased by 61% from 2000 through 2016; and in the next 10 years, is expected to jump by a further 41%.

This partnership will support innovation and industry-driven, applied research in Alberta’s life science sector through three areas of focus:

Social and Clinical Determinants of Diabetes-Obesity

Improve diabetes-obesity interventions and management in the community setting for the most vulnerable patients who are living with diabetes and obesity.  Design and apply health innovations to these populations in a select primary care network in Alberta.

Healthy Aging in Community Setting

Through Alberta health based innovations, enhance diabetes-obesity interventions and management for seniors to help support independent living and delayed care utilization.

Improving Acute Care Initiative

In Canada, roughly 1 in 5 hospital admissions will be a person living with diabetes, with around 40% of these patients on insulin. Through this focus, Alberta based innovations would be used to achieve consistent, safe blood glucose control as measured by A1c –and other improved health outcomes.


 

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given the organization experience and capabilities that also enable them to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com.

About Alberta Economic Development and Trade

The Ministry of Alberta Economic Development and Trade focuses on economic growth and diversification by supporting innovation and research; expanding access to capital for small and medium-sized enterprises; promoting trade, investment and market access initiatives; and leading Alberta’s negotiations on trade agreements. Learn more at http://economic.alberta.ca.

Donor Office - University of Alberta Hospital

1H1.91 WMC, 8440 – 112 Street NW, Edmonton, AB T6G 2B7

Donor Office - Mazankowski Alberta Heart Institute

2A9.006 MAHI, 8440 – 112 Street NW, Edmonton, AB T6G 2B7

Donor Office - Kaye Edmonton Clinic

1B.120 KEC, 11400 University Avenue, Edmonton, AB T6G 1Z1

University Hospital Foundation

Phone: 780-407-7007 | Fax: 780-407-6603
uhfoundation@albertahealthservices.ca
Charitable Registration Number  88900-3240 RR0001

 

     AHP High Performer 2017     

 

 

Copyright 2018 University Hospital Foundation